AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ALLERGY THERAPEUTICS PLC

Regulatory Filings Apr 25, 2014

7477_dirs_2014-04-25_6e934b2a-9a3e-4905-a155-ef18d495dcb3.html

Regulatory Filings

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4873F

Allergy Therapeutics PLC

25 April 2014

25 April 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Grant of Options

Allergy Therapeutics plc (AIM: AGY) announces that, pursuant to the Allergy Therapeutics plc Long Term Share Incentive Plan ('LTIP') on 24 April 2014 provisional shares of 0.1 pence each in the share capital of the Company were awarded to the following Board Directors, Mr Manuel Llobet (Chief Executive Officer) and Mr Ian Postlethwaite (Finance Director) at nil cost, as follows:

Director Number of provisional shares awarded Date of distribution Total provisional shares held under LTIPs
Manuel Llobet 845,000 24 April 2014 3,190,000
Ian Postlethwaite 422,500 24 April 2014 1,595,000

The issuance and distribution of ordinary shares of 0.1 pence each under the LTIP is conditional on the Company's performance over the course of three years. The new Long Term Incentive Plan was adopted by the Board on 20 March 2013.

-Ends-

For further information

Allergy Therapeutics +44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Peel Hunt LLP +44 (0) 20 7418 8900
James Steel / Clare Terlouw
FTI Consulting +44 (0) 20 3727 1000
Simon Conway/ Mo Noonan / Victoria Foster-Mitchell

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination.  It has a growing business achieving sales in the prior financial year of almost £40 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.  The Company is expanding its infrastructure into the Emerging Markets.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBLGDSUUDBGSS

Talk to a Data Expert

Have a question? We'll get back to you promptly.